- Home
- PNI vs ACET Comparison
PNI vs ACET Comparison
Compare PNI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | ACET |
|---|---|---|
| Founded | 2002 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.8M | 77.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PNI | ACET |
|---|---|---|
| Price | $7.01 | $9.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | ★ 80.0K | 65.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.43 | $0.46 |
| 52 Week High | $7.20 | $9.47 |
Technical Indicators
Market Signals| Indicator | PNI | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 62.07 |
| Support Level | $6.94 | $7.02 |
| Resistance Level | $7.07 | $9.47 |
| Average True Range (ATR) | 0.06 | 0.45 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 11.11 | 86.50 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).